CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF44 (ImmuneEditome ID:51710)

1. Gene summary of enriched editing regions for ZNF44

check button Gene summary
Gene informationGene symbol

ZNF44

Gene ID

51710

GeneSynonymsGIOT-2|KOX7|ZNF|ZNF504|ZNF55|ZNF58
GeneCytomap

19p13.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 44|gonadotropin inducible transcription repressor-2|gonadotropin-inducible ovary transcription repressor 2|zinc finger protein 55|zinc finger protein 58|zinc finger protein KOX7|zinc finger protein ZnFP12
GeneModificationdate20230515
UniprotIDM0R160;P15621;E2QRP2;F8W7T7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:12239775-12240382:-ENST00000600003.4ENSG00000197857.12ZNF44intronicAluSg,AluSz,L1MB4chr19:12239775-12240382:-.alignment
chr19:12245724-12246986:-ENST00000600003.4ENSG00000197857.12ZNF44intronicLTR33C,AluJrchr19:12245724-12246986:-.alignment
chr19:12267966-12269380:-ENST00000393337.6ENSG00000197857.12ZNF44intronicAluJr,AluJb,AluSx,(AC)n,AluSq2,L1M4,MER34-intchr19:12267966-12269380:-.alignment
chr19:12267966-12269380:-ENST00000397742.6ENSG00000197857.12ZNF44intronicAluJr,AluJb,AluSx,(AC)n,AluSq2,L1M4,MER34-intchr19:12267966-12269380:-.alignment
chr19:12267966-12269380:-ENST00000600003.4ENSG00000197857.12ZNF44intronicAluJr,AluJb,AluSx,(AC)n,AluSq2,L1M4,MER34-intchr19:12267966-12269380:-.alignment
chr19:12272102-12272294:-ENST00000356109.8ENSG00000197857.12ZNF44UTR3AluSx3chr19:12272102-12272294:-.alignment
chr19:12278555-12280181:-ENST00000354656.3ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12278555-12280181:-ENST00000355684.5ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12278555-12280181:-ENST00000356109.8ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12278555-12280181:-ENST00000393337.6ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12278555-12280181:-ENST00000397742.6ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12278555-12280181:-ENST00000600003.4ENSG00000197857.12ZNF44intronicL1MCa,AluJr,AluSx,FLAM_C,L1MB4,(TG)nchr19:12278555-12280181:-.alignment
chr19:12282524-12282744:-ENST00000354656.3ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12282524-12282744:-ENST00000355684.5ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12282524-12282744:-ENST00000356109.8ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12282524-12282744:-ENST00000393337.6ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12282524-12282744:-ENST00000397742.6ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12282524-12282744:-ENST00000600003.4ENSG00000197857.12ZNF44intronicLTR44,AluSx1chr19:12282524-12282744:-.alignment
chr19:12285339-12287431:-ENST00000354656.3ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12285339-12287431:-ENST00000355684.5ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12285339-12287431:-ENST00000356109.8ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12285339-12287431:-ENST00000393337.6ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12285339-12287431:-ENST00000397742.6ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12285339-12287431:-ENST00000600003.4ENSG00000197857.12ZNF44intronicL1PB4,L1MEf,AluSc8,MER5A,AluY,AluSg7,AluSz,(TA)n,AluSq2chr19:12285339-12287431:-.alignment
chr19:12289628-12289926:-ENST00000354656.3ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment
chr19:12289628-12289926:-ENST00000355684.5ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment
chr19:12289628-12289926:-ENST00000356109.8ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment
chr19:12289628-12289926:-ENST00000393337.6ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment
chr19:12289628-12289926:-ENST00000397742.6ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment
chr19:12289628-12289926:-ENST00000600003.4ENSG00000197857.12ZNF44intronicMER92B,AluYchr19:12289628-12289926:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF44


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:12245724-12246986:-KIRPEER1.1008e-024.6624e-026.6290e+01image

Top

3. Enriched editing regions and immune related genes for ZNF44


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ZNF44


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for ZNF44


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:12245724-12246986:-BRCAEERB_cells_memory3.5931e-040.1385image
chr19:12267966-12269380:-BRCAEERT_cells_CD4_memory_resting4.7220e-02-0.3240image
ENSG00000197857.12,ZNF44BRCAEAGB_cells_memory2.2073e-040.1399image
ENSG00000197857.12,ZNF44CESCEAGT_cells_CD4_memory_activated1.3927e-02-0.4516image
ENSG00000197857.12,ZNF44COADEAGMacrophages_M12.1817e-02-0.3304image
chr19:12245724-12246986:-ESCAEERT_cells_regulatory_(Tregs)3.1529e-02-0.2734image
chr19:12285339-12287431:-ESCAEERMacrophages_M16.9908e-03-0.5699image
chr19:12289628-12289926:-ESCAEERMonocytes4.7671e-020.2969image
ENSG00000197857.12,ZNF44ESCAEAGMonocytes4.4087e-020.1932image
chr19:12245724-12246986:-KICHEERT_cells_CD84.1669e-020.3196image
ENSG00000197857.12,ZNF44KIRCEAGDendritic_cells_resting2.6591e-020.1541image
ENSG00000197857.12,ZNF44LAMLEAGMacrophages_M11.1917e-020.2494image
chr19:12245724-12246986:-LIHCEERMacrophages_M01.1845e-02-0.3605image
ENSG00000197857.12,ZNF44LIHCEAGMast_cells_activated2.1588e-020.3065image
chr19:12245724-12246986:-LUSCEERMonocytes4.1419e-02-0.4192image
chr19:12245724-12246986:-OVEERT_cells_CD85.0810e-030.2532image
chr19:12289628-12289926:-OVEERT_cells_follicular_helper2.0246e-030.5980image
ENSG00000197857.12,ZNF44OVEAGMacrophages_M12.1546e-020.1794image
ENSG00000197857.12,ZNF44PAADEAGB_cells_memory1.5331e-030.5447image
chr19:12245724-12246986:-PCPGEERT_cells_follicular_helper1.3550e-02-0.3146image
ENSG00000197857.12,ZNF44PCPGEAGT_cells_follicular_helper7.1301e-03-0.3167image
chr19:12245724-12246986:-PRADEERB_cells_memory6.0460e-040.2724image
ENSG00000197857.12,ZNF44PRADEAGT_cells_CD4_memory_activated1.0107e-02-0.1962image
chr19:12245724-12246986:-SARCEERNK_cells_resting2.9287e-020.2816image
ENSG00000197857.12,ZNF44SARCEAGT_cells_CD4_memory_activated3.8073e-02-0.2450image
ENSG00000197857.12,ZNF44SKCMEAGT_cells_gamma_delta1.8329e-020.4023image
chr19:12245724-12246986:-STADEERT_cells_follicular_helper2.3648e-020.1954image
chr19:12285339-12287431:-STADEERMacrophages_M02.2084e-02-0.3231image
ENSG00000197857.12,ZNF44THYMEAGDendritic_cells_activated9.2217e-030.4750image


Top

6. Enriched editing regions and immune gene sets for ZNF44


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:12245724-12246986:-BRCAEER2.9765e-060.18077.9723e-030.10323.1333e-020.08381.8590e-040.1450image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:12245724-12246986:-BRCAGSVA_HALLMARK_UV_RESPONSE_UPEER1.0605e-070.2051image
ENSG00000197857.12,ZNF44BRCAGSVA_HALLMARK_GLYCOLYSISEAG2.6866e-040.1380image
chr19:12267966-12269380:-BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.7625e-020.3385image
ENSG00000197857.12,ZNF44CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2643e-02-0.4572image
chr19:12245724-12246986:-ESCAGSVA_HALLMARK_HEME_METABOLISMEER2.8699e-02-0.2780image
ENSG00000197857.12,ZNF44GBMGSVA_HALLMARK_APICAL_JUNCTIONEAG2.3043e-02-0.2774image
chr19:12245724-12246986:-GBMGSVA_HALLMARK_APICAL_JUNCTIONEER9.6602e-03-0.3289image
chr19:12245724-12246986:-KIRCGSVA_HALLMARK_UV_RESPONSE_UPEER2.8247e-040.2547image
ENSG00000197857.12,ZNF44KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG3.2535e-050.2845image
chr19:12245724-12246986:-KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.0692e-03-0.2991image
ENSG00000197857.12,ZNF44LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.5535e-020.2222image
ENSG00000197857.12,ZNF44LGGGSVA_HALLMARK_HEME_METABOLISMEAG3.3717e-020.1124image
chr19:12245724-12246986:-LGGGSVA_HALLMARK_HEME_METABOLISMEER1.6857e-020.1270image
chr19:12245724-12246986:-LIHCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.6741e-020.3023image
ENSG00000197857.12,ZNF44LIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG3.9022e-020.2766image
ENSG00000197857.12,ZNF44LUADGSVA_HALLMARK_UV_RESPONSE_DNEAG4.1441e-020.2377image
ENSG00000197857.12,ZNF44LUSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.0276e-02-0.4338image
chr19:12245724-12246986:-LUSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.3241e-02-0.4981image
chr19:12245724-12246986:-OVGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.9374e-020.2123image
ENSG00000197857.12,ZNF44OVGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.4303e-030.2212image
chr19:12289628-12289926:-OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.8194e-020.4778image
ENSG00000197857.12,ZNF44PAADGSVA_HALLMARK_MYC_TARGETS_V2EAG2.3463e-02-0.4059image
chr19:12245724-12246986:-PCPGGSVA_HALLMARK_DNA_REPAIREER1.7057e-020.3044image
ENSG00000197857.12,ZNF44PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.3480e-030.3732image
chr19:12245724-12246986:-PRADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER9.1643e-03-0.2087image
ENSG00000197857.12,ZNF44PRADGSVA_HALLMARK_MYC_TARGETS_V1EAG2.3604e-020.1731image
chr19:12245724-12246986:-SKCMGSVA_HALLMARK_COAGULATIONEER5.1513e-030.5418image
ENSG00000197857.12,ZNF44SKCMGSVA_HALLMARK_MYC_TARGETS_V1EAG1.2168e-02-0.4253image
chr19:12245724-12246986:-STADGSVA_HALLMARK_SPERMATOGENESISEER4.0513e-020.1772image
chr19:12278555-12280181:-STADGSVA_HALLMARK_ANDROGEN_RESPONSEEER8.4219e-030.3458image
chr19:12285339-12287431:-STADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER7.1842e-030.3756image
ENSG00000197857.12,ZNF44STADGSVA_HALLMARK_HEME_METABOLISMEAG1.6003e-030.2175image
chr19:12245724-12246986:-THCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER8.4993e-040.1716image
ENSG00000197857.12,ZNF44THCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.3200e-050.2026image


Top

7. Enriched editing regions and drugs for ZNF44


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000197857.12,ZNF44BLCAFH535EAG1.1064e-02-0.3795image
chr19:12267966-12269380:-BRCAEHT.1864EER2.3776e-020.3661image
ENSG00000197857.12,ZNF44BRCACCT007093EAG5.6883e-040.1306image
chr19:12245724-12246986:-BRCACCT007093EER1.3400e-090.2332image
chr19:12245724-12246986:-CESCKU.55933EER2.3498e-020.4704image
ENSG00000197857.12,ZNF44CESCKU.55933EAG1.0785e-030.5759image
ENSG00000197857.12,ZNF44COADBleomycinEAG9.4772e-030.3708image
chr19:12245724-12246986:-ESCACytarabineEER1.8677e-02-0.2979image
chr19:12285339-12287431:-ESCAElesclomolEER4.5359e-03-0.5938image
ENSG00000197857.12,ZNF44ESCAIPA.3EAG2.0642e-03-0.2933image
chr19:12289628-12289926:-ESCAIPA.3EER2.9607e-03-0.4378image
ENSG00000197857.12,ZNF44GBMJNK.9LEAG2.6880e-030.3610image
chr19:12245724-12246986:-GBMAS601245EER1.7183e-030.3932image
ENSG00000197857.12,ZNF44KICHBMS.708163EAG1.8511e-030.4563image
chr19:12245724-12246986:-KICHBMS.708163EER3.3870e-030.4470image
chr19:12245724-12246986:-KIRCCCT007093EER2.4218e-030.2138image
ENSG00000197857.12,ZNF44KIRCBicalutamideEAG3.4521e-03-0.2024image
ENSG00000197857.12,ZNF44KIRPAS601245EAG9.5807e-030.2529image
chr19:12245724-12246986:-KIRPLapatinibEER8.8169e-030.2660image
ENSG00000197857.12,ZNF44LAMLAP.24534EAG5.0802e-030.2768image
chr19:12245724-12246986:-LGGABT.263EER5.3999e-030.1476image
ENSG00000197857.12,ZNF44LIHCBAY.61.3606EAG2.1959e-02-0.3057image
ENSG00000197857.12,ZNF44OVBicalutamideEAG2.2388e-02-0.1783image
chr19:12289628-12289926:-OVABT.263EER5.0652e-03-0.5530image
chr19:12245724-12246986:-PCPGBIBW2992EER3.4102e-020.2718image
ENSG00000197857.12,ZNF44PCPGCI.1040EAG4.9912e-030.3297image
chr19:12245724-12246986:-PRADAxitinibEER1.6983e-03-0.2501image
ENSG00000197857.12,ZNF44PRADGSK.650394EAG1.8873e-03-0.2360image
ENSG00000197857.12,ZNF44SARCEmbelinEAG2.0062e-02-0.2736image
chr19:12245724-12246986:-SKCMAUY922EER1.0121e-03-0.6173image
ENSG00000197857.12,ZNF44SKCMAZD.0530EAG1.2038e-03-0.5320image
chr19:12278555-12280181:-STADCytarabineEER2.5159e-030.3927image
ENSG00000197857.12,ZNF44STADGefitinibEAG3.4125e-020.1470image
ENSG00000197857.12,ZNF44THCAAMG.706EAG3.2404e-030.1483image
chr19:12245724-12246986:-THCAAG.014699EER1.0065e-020.1328image
ENSG00000197857.12,ZNF44THYMAZD7762EAG1.1227e-02-0.4640image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType